Medical Tidbits, Researchers say a new test to detect Lyme disease is highly inaccurate

clinical sales jobs

A new microscopy technique (LM-method) developed to detect Lyme disease is unable to distinguish infected patients from healthy controls, yielding false-positive results that could lead doctors to over-diagnose a patient, according to new research published in the journal Infectious Diseases .

The new research follows up on a previous study suggesting that modified microscopy techniques (LM-method) could detect active cases of Lyme disease (caused by Borrelia bacteria) and Babesia (a tick-borne malaria-like parasite) in just one to two days. Despite considerable publicity and patient demand for this test in Norway, earlier studies did not include a control group and methods were not validated and ready for use in patients. read more

FDA approves implantable device that changes the shape of the cornea to correct near vision
The U.S. Food and Drug Administration today approved the Raindrop Near Vision Inlay, a device implanted in the cornea (the clear, front surface) of one eye to improve near vision in certain patients with presbyopia. It is the second FDA-approved implantable corneal device for correction of near vision in patients who have not had cataract surgery and the first implantable device that changes the shape of the cornea to achieve improved vision. read more
Moberg Pharma enters into a definitive agreement to acquire three U.S. OTC brands from Prestige BrandsSTOCKHOLM, June 30, 2016. Moberg Pharma AB (OMX: MOB) has signed an agreement to acquire New Skin®, Fiber Choice® and PediaCare®, threewell-established Over-The-Counter brands in the U.S. from Prestige Brands, Inc. In the latest 12 months ending March 31, 2016, the Net sales of these brands was approximately $24.4 million. The purchase price is $40 million and Moberg Pharma expects the acquired brands to contribute to its EBITDA with approximately $5 million for the 12 months following closing of the transaction. The acquisition is financed by available cash resources and a tap issue to Moberg’s outstanding bond loan.


Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance  New partners are joining founding members Merck, Illumina and Genea to support standardization of processes in assisted reproductive treatment laboratories  Update on the alliance’s activities to be presented at ESHRE

Darmstadt, Germany, June 30, 2016 – Merck, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and Genea Limited, Sydney, Australia, that the Global Fertility Alliance welcomed two new members. The alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory read more

Baxter Announces Health Canada Approval of AMIA Automated Peritoneal Dialysis System with SHARESOURCE Connectivity Platform

    • Baxter expands successful launch of AMIA with SHARESOURCE to include Canada

    • Canadian home dialysis patients to gain access to therapy with two-way connectivity with healthcare team

  • AMIA operator-friendly features designed so more patients can manage therapy at home

MISSISSAUGA, ONTARIO, June 29, 2016 – Baxter International Inc. (NYSE: BAX) is expanding the introduction of its AMIA Automated Peritoneal Dialysis (APD) System with the SHARESOURCE Connectivity Platform to Canada with the announcement that Health Canada recently approved the system. The AMIA APD and SHARESOURCE system is the first APD device cleared in the United States and Canada to include patient-centric features such as voice guidance, a touchscreen control panel and two-way telemedicine capabilities for remote patient management. read more

Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results | Pfizer: One of the world’s premier biopharmaceutical companies SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular eventsPfizer Inc. announced two additional Phase 3 bococizumab trials, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among adults at high and very high risk for cardiovascular events who were receiving a maximally tolerated dose of a highly effective statin. read more

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.